Diaceutics (LON:DXRX) Trading 1% Higher - Should You Buy?

Diaceutics PLC (LON:DXRX - Get Free Report)'s stock price shot up 1% during mid-day trading on Friday . The stock traded as high as GBX 145 ($1.83) and last traded at GBX 143.90 ($1.82). 39,528 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 123,055 shares. The stock had previously closed at GBX 142.50 ($1.80).

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DXRX. Canaccord Genuity Group restated a "buy" rating and issued a GBX 160 ($2.02) price target on shares of Diaceutics in a research report on Tuesday, December 17th. Canaccord Genuity Group restated a "buy" rating and set a GBX 160 ($2.02) target price on shares of Diaceutics in a report on Tuesday, December 17th.

Diaceutics Stock Up 1.0 %

The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92. The firm's 50 day moving average is GBX 136.13 and its two-hundred day moving average is GBX 129.22. The firm has a market capitalization of £121.44 million, a P/E ratio of -42.68 and a beta of 0.58.

Insiders Place Their Bets

In other news, insider Graham Paterson bought 11,643 shares of the company's stock in a transaction dated Thursday, January 30th. The stock was bought at an average price of GBX 138 ($1.74) per share, with a total value of £16,067.34 ($20,299.86). Company insiders own 34.30% of the company's stock.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.